In a follow up to its 2022 consensus statement on lipoprotein(a) [Lp(a)],1 the European Atherosclerosis Society (EAS) has published the answers to 30 of the most frequently asked questions about how the recommendations affect everyday clinical practice and management of atherosclerotic cardiovascular disease (ASCVD).2 They include:
